GLP-1 Compounding: Demand & Quality Concerns
- The increasing demand for compounded medications, driven partly by direct-to-consumer advertising and drug shortages, has amplified concerns regarding their safety, quality, and regulation.
- Unlike standard prescription drugs, compounded medications aren't subject to the FDA's premarket approval process.While organizations like the United States Pharmacopeia and state pharmacy boards offer some oversight,the FDA's...
- A prime example involves glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic, Wegovy), initially approved for diabetes and heart disease but now popular for weight loss.
Rising demand for compounded medications, especially GLP-1 drugs, fuels notable quality and safety concerns. The FDA’s less stringent regulation of compounded drugs highlights the critical need for complete oversight. Direct-to-consumer advertising, coupled with drug shortages, is driving increased interest in compounded alternatives for weight loss. Accreditation, like that offered by PCAB, is emerging as a key factor in ensuring patient safety amidst this landscape, demanding stringent quality control as a cornerstone of operation. News Directory 3 analyzes the implications of these trends, looking closely at the risks related to inconsistent formulations and the reports of adverse events. Discover what’s next in compounded drug oversight and how accreditation offers a path forward.
Accreditation Key to Safety of Compounded Drugs amidst Rising demand
Updated June 27, 2024
The increasing demand for compounded medications, driven partly by direct-to-consumer advertising and drug shortages, has amplified concerns regarding their safety, quality, and regulation. Accreditation is emerging as a critical factor in ensuring the integrity of compounding practices.
Unlike standard prescription drugs, compounded medications aren’t subject to the FDA’s premarket approval process.While organizations like the United States Pharmacopeia and state pharmacy boards offer some oversight,the FDA’s limited regulation of compounded drugs can lead to inconsistencies in quality control and safety.
A prime example involves glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic, Wegovy), initially approved for diabetes and heart disease but now popular for weight loss. A recent KFF poll indicated that 1 in 8 Americans have used a GLP-1 medication, with 40% using it for weight loss. A survey by Virta Health showed that nearly 9 in 10 physicians expect GLP-1 prescriptions to at least double this year.
The surge in demand has led to shortages, prompting the creation of compounded versions and raising safety concerns. A Fierce Healthcare survey revealed that 42% of physicians advise against using compounded GLP-1 drugs for weight loss due to safety and regulatory worries. Over 100 telehealth platforms market these medications, often without proper medical oversight.
Compounded medications may lack standardization, contain unverified ingredients, and be produced in facilities with varying quality control levels. The FDA has received reports of adverse events linked to compounded GLP-1 drugs, especially with incorrect dosages or formulation issues.
Direct-to-consumer marketing, exemplified by Hims & hers’ Super Bowl ad for GLP-1s as a weight loss solution, has further complicated the issue. While Hims & Hers saw its stock value surge, the FDA later removed semaglutide from the drug shortage list, setting April 22, 2025, as the date beyond which these drugs can no longer be legally compounded.
The Pharmacy Compounding Accreditation Board (PCAB),a service of ACHC,is considered a benchmark for quality in compounding.PCAB accreditation ensures compounded medications meet stringent standards, requiring comprehensive quality control, contamination prevention, and proper training for pharmacists and technicians.
PCAB accreditation also supports patient safety by ensuring responsible dispensing within an established patient-physician relationship. Accredited pharmacies demonstrate a commitment to best practices in sterile and nonsterile compounding, mitigating risks associated with inconsistencies, contamination, and improper formulation.
What’s next
The compounding pharmacy industry faces the challenge of balancing innovation with safety. While personalized medicine and drug shortages drive demand, maintaining the quality and integrity of compounded drugs remains paramount. PCAB accreditation offers a framework for pharmacies to meet these challenges, reinforcing public trust as healthcare evolves.